Global food manufacturer Danone has reported sales of €6,708 million during the first quarter, up by 2.7% on a like-for-like basis.
Danone described a “resilient performance” in the Europe, Middle East and Africa (EMEA) region amid the conflict in the Middle East, with Q1 2026 bringing in revenue of €2,959 million. This was down by 1.6% on Q1 2025’s €3,007 million.
Guidance for 2026 was in line with mid-term ambition, with like-for-like sales growth expected between 3% and 5%. Danone said its recurring operating income would grow faster than its sales.
The company reported improved growth in the Americas, driven by “continued strong performance” in Latin America. Danone said its Asia Pacific region had a “solid performance”, driven by its specialised nutrition category in China and essential dairy and plant-based category in Japan.
“Our winning platforms continued to perform strongly, notably in dairy with high protein, skyr and kefir.”
Antoine de Saint-Affrique, CEO of Danone, commented: “This first quarter demonstrated again the resilience, strength and relevance of our health focused portfolio: against a challenging backdrop, we delivered a solid performance of +2.7% LFL, driven by positive volume/mix across all categories. Our winning platforms continued to perform strongly, notably in dairy with high protein, skyr and kefir, in Waters with evian and Mizone, as well as in medical nutrition around the globe.
“We accelerated our transformation with the signing of two transactions that will further strengthen our portfolio: the acquisition of Huel, extending our presence in the fast-growing complete nutrition space, and the creation of a dairy joint venture with Arcor, unlocking new opportunities in Argentina. Meanwhile, we remained constructively dissatisfied and focused on delivering on our priorities and addressing the areas that still require further progress.
“In a world that remains volatile and uncertain, we stay disciplined and fully focused on executing on our Renew strategy. We are confident in our science based, and consumer and patient centric approach and confirm our full year guidance.”
